No­var­tis turns to BeiGene again for the next big check­point tar­get, pay­ing $300M to jump in­to TIG­IT race

Count No­var­tis in for the bur­geon­ing TIG­IT race.

Af­ter start­ing the year by plunk­ing down $650 mil­lion up­front to li­cense BeiGene’s PD-1 in­hibitor — with pos­i­tive Phase III da­ta stack­ing up ever since — No­var­tis is re­turn­ing to its biotech part­ner to pick up a Phase III TIG­IT drug while en­trust­ing it with mar­ket­ing five of its ap­proved can­cer treat­ments in Chi­na.

Their goal, BeiGene CEO John Oyler sug­gests in an in­ter­view with End­points News, is noth­ing short of vault­ing to a lead­er­ship po­si­tion in the TIG­IT space with the ad­di­tion­al horse­pow­er that No­var­tis brings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER